文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Visceral Leishmaniasis in Southwestern Iran: A Retrospective Clinico-Hematological Analysis of 380 Consecutive Hospitalized Cases (1999-2014).

作者信息

Sarkari Bahador, Naraki Tahereh, Ghatee Mohammad Amin, Abdolahi Khabisi Samaneh, Davami Mohammad Hassan

机构信息

Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

出版信息

PLoS One. 2016 Mar 4;11(3):e0150406. doi: 10.1371/journal.pone.0150406. eCollection 2016.


DOI:10.1371/journal.pone.0150406
PMID:26942443
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4778872/
Abstract

Visceral Leishmaniasis (VL) is an endemic parasitic disease and remains as a major health concern in southwestern Iran. The current study describes clinico-hematological, epidemiological and therapeutic features of VL cases, admitted to university-affiliated hospitals, during 1999-2014 in Fars province, southwestern Iran. A total of 380 VL cases were recorded during a 16 years period, giving an average annual admission of 23.75 cases/year in which 217 (57.1%) were male and 163 (42.9%) were female. Mean age of the patients was 3.7 years. The majority of the cases (91.5%) were ≤ 5 years old. Bone-marrow aspiration detected Leishmania amastigotes only in 26.6% of cases. Fever (98.1%), abdominal protrusion (65.1%) and hepatosplenomegaly (63.7%) were the most common clinical presentations of the patients. Pancytopenia was noted in 43.1, anemia in 87.3 and thrombocytopenia in 64% of cases. Increase in the level of AST (aspartate aminotransferase), ALT (alanine aminotransferase), alkaline phosphatase, LDH (lactate dehydrogenase) and CRP (C-Reactive Proteins) were seen in 84.9, 53.6, 44.4, 72.5 and 83.1% of cases, respectively. Mortality was noted in 5.3% of cases. Deranged haemato-biochemical parameters including total and direct bilirubin, PLT (platelet) and pancytopenia were significantly contributed to mortality from VL. Moreover, clinical features such as severe splenomegaly as well as bacterial infections were meaningfully contributed to death from VL. The majority of patients (74.9%) were treated with meglumine antimoniate. Amphotericin B was administrated in 59 of cases, 11 of them were initially treated with meglumine antimoniate with a shift to amphotericin B, because of treatment failure. Findings of the current study demonstrated that VL is present in southwest of Iran with a fairly continual rate during the last 16 years period. Deranged haemato-biochemical parameters along with severe splenomegaly contributed to mortality from VL.

摘要

相似文献

[1]
Visceral Leishmaniasis in Southwestern Iran: A Retrospective Clinico-Hematological Analysis of 380 Consecutive Hospitalized Cases (1999-2014).

PLoS One. 2016-3-4

[2]
Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?

AIDS. 1992-12

[3]
Epidemiological and clinical features of visceral leishmaniasis in children in Alicante Province, Spain.

Paediatr Int Child Health. 2018-8

[4]
Visceral leishmaniasis in 13 pediatric patients in Turkey: treatment experience.

Turkiye Parazitol Derg. 2009

[5]
Pediatric visceral leishmaniasis in Albania: a retrospective analysis of 1,210 consecutive hospitalized patients (1995-2009).

PLoS Negl Trop Dis. 2010-9-7

[6]
Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.

Eur J Clin Microbiol Infect Dis. 2002-4

[7]
Visceral leishmanisis in paediatrics: a study of 367 cases in southwest Iran.

Trop Doct. 2008-7

[8]
[Evaluation of clinical and laboratory findings of adult visceral leishmaniasis cases].

Mikrobiyol Bul. 2015-10

[9]
Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.

Rev Inst Med Trop Sao Paulo. 2015

[10]
Visceral leishmaniasis without fever in an 11-month-old infant: a rare clinical feature of Kala-azar.

Korean J Parasitol. 2014-4

引用本文的文献

[1]
Insights to the HIV-associated visceral leishmaniasis clinical outcome: lessons learned about immune mediated disorders.

Front Immunol. 2025-3-12

[2]
Identification of CβS and ODC antimony resistance markers in anthroponotic cutaneous leishmaniasis field isolates by gene expression profiling.

Parasite Epidemiol Control. 2025-1-23

[3]
Hematological picture of pediatric Sudanese patients with visceral leishmaniasis and prediction of leishmania donovani parasite load.

World J Clin Cases. 2024-10-26

[4]
Visceral Leishmaniasis (VL) Clinical Presentation, Laboratory Findings, Treatment Options and Outcome.

Iran J Parasitol. 2024

[5]
Infection in Synanthropic Rodents: Evidence for the Urbanization of Zoonotic Cutaneous Leishmaniasis (ZCL) in Southern Iran.

Can J Infect Dis Med Microbiol. 2024-3-7

[6]
Elucidating the role played by bone marrow in visceral leishmaniasis.

Front Cell Infect Microbiol. 2023

[7]
Management of Liver Hydatid Cysts: A Retrospective Analysis of 293 Surgical Cases from Southern Iran.

J Trop Med. 2023-6-19

[8]
Epidemiological, clinical and hematological profiles of visceral leishmaniasis among patients visiting Tefera Hailu Memorial Hospital, Northeast Ethiopia: a 4 year retrospective study.

Sci Rep. 2023-1-17

[9]
Visceral Leishmaniasis in Ardabil Province, Northwest of Iran: A Retrospective Epidemiological, Clinical and Paraclinical Study (1985-2018).

Iran J Public Health. 2022-8

[10]
Diagnostic Performance of Three rK39 Rapid Diagnostic Tests and Two Direct Agglutination Tests for the Diagnosis of Visceral Leishmaniasis in Southern Iran.

J Trop Med. 2022-4-11

本文引用的文献

[1]
Visceral leishmaniasis in Iran: Review of the Epidemiological and Clinical Features.

Iran J Parasitol. 2013-7

[2]
Molecular identification and polymorphism determination of cutaneous and visceral leishmaniasis agents isolated from human and animal hosts in Iran.

Biomed Res Int. 2013-10-28

[3]
Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.

Expert Rev Anti Infect Ther. 2013-1

[4]
Epidemiological features of visceral leishmaniasis in fars province, southern iran.

Iran J Public Health. 2012

[5]
Recent advances in the diagnosis and treatment of kala-azar.

Natl Med J India. 2012

[6]
Hematologic changes in visceral leishmaniasis/kala azar.

Indian J Hematol Blood Transfus. 2010-9

[7]
Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.

Southeast Asian J Trop Med Public Health. 2011-5

[8]
An observational study on the current distribution of visceral leishmaniasis in different geographical zones of Iran and implication to health policy.

Travel Med Infect Dis. 2011-3-17

[9]
Seroepidemiological study of visceral leishmaniasis in Booyerahmad district, south-west Islamic Republic of Iran.

East Mediterr Health J. 2010-11

[10]
Risk factors for death in children with visceral leishmaniasis.

PLoS Negl Trop Dis. 2010-11-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索